SANTA
CLARA, Calif., Oct. 26,
2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a company that develops, manufactures and markets innovative
medical products and services that assist in evaluating and
treating chronic diseases, today announced that it will report
financial results for the third quarter and first nine months ended
September 30, 2023, after the close
of U.S. financial markets on Thursday,
November 9, 2023. Doug
Murphy-Chutorian, M.D., chief executive officer of Semler
Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, and
Jennifer Oliva-Herrington, chief
operating officer, will join him on the call.
We encourage participants to pre-register for the conference
call using the following link:
https://dpregister.com/sreg/10182979/fa8e2b792d.
Callers who pre-register will be given a conference passcode and
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may pre-register at any time, including up
to and after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 866-777-2509
International callers: 412-317-5413
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific, Inc. develops, manufactures and markets
innovative products and services that assist in evaluating and
treating chronic diseases. Its flagship product,
QuantaFlo®, which is patented and cleared by the U.S.
Food and Drug Administration (FDA), is a rapid point-of-care test
that measures arterial blood flow in the extremities. The
QuantaFlo® test aids in the diagnosis of cardiovascular
diseases, such as peripheral arterial disease (PAD) and heart
dysfunction (HD). QuantaFlo® is used by healthcare
providers to evaluate their patient's risk of mortality and major
adverse cardiovascular events (MACE). In addition, Semler
Scientific has an agreement with Mellitus Health, Inc. (Mellitus)
to exclusively market and distribute Insulin Insights™, an
FDA cleared software product that recommends optimal insulin dosing
for diabetic patients in the United
States, including Puerto
Rico. Semler Scientific has a minority investment in
Mellitus, as well as Monarch Medical Technologies LLC, a privately
held company whose product EndoTool® offers a
technological solution for inpatient glycemic management.
Additional information about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Renae Cormier, CFO
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-report-third-quarter-and-first-nine-months-of-2023-financial-results-and-host-conference-call-on-november-9-2023-301969289.html
SOURCE Semler Scientific, Inc.